Opinion: If 2021 is to be the year of U.S. drug price controls, how should biopharma companies respond?
As the Biden administration assumes leadership in Washington and former President Donald Trump’s most-favored nation ruling has been halted by a federal judge, drug price controls don’t feel imminent.
Though this should provide some relief to the R&D-based biopharmaceutical industry, the relief may be short-lived.
